Chipotle is installing a back-of-house retrofit it calls the High-Efficiency Equipment Package where equipped restaurants are turning out two to three more entrées in their peak fifteen-minute window than the rest of the system, which management says translates into hundreds o...
Read Article ›The market repriced the whole company for a disruption thesis about Legal; yet Legal supplies roughly an eighth of group profit and it is the division that sped up.
Read Article ›The market is still pricing Devon as though 40% of its barrels will go on earning 2% of its revenue, and that is the one thing about this company that is already changing
Read Article ›At about 18x 2027 earnings, with net cash, a 5.7% free cash flow yield and an unused repurchase authorization underneath it, TechnipFMC is mispriced.
Read Article ›In the June quarter, the company finished the hardest thing it has attempted in decades: cutting Amazon's volume by more than half from 2024 levels, roughly two million pieces a day, alongside some 78,000 operational positions, close to 150 buildings, and about $4.5 billion of...
Read Article ›At 23x forward earnings, with every segment's operating metrics improving, the market is underpricing RTX's near-term operational momentum: aircraft on ground falling, Collins cost actions landing, Raytheon converting a 2.4x book-to-bill.
Read Article ›The market has marked down a franchise for a threat it cannot yet feel, and at 37 times forward earnings Howmet is worth owning — not for a re-rating to $328, but because the business is compounding faster than the multiple needs to expand.
Read Article ›The earnings that justify the multiple are largely ordered rather than hoped for, lithography intensity in memory is rising in a way that shows up in revenue per tool rather than only in management's framing, and the next disclosure that matters is more likely to lift 2028 est...
Read Article ›The market is not underpricing Enterprise Products Partners so much as pricing it correctly as a spread product and then marking it against a Treasury curve that has moved violently.
Read Article ›A bank that spent seven years unable to grow has spent fifteen months deploying a balance sheet into markets financing, commercial relationships, and an investment bank taking measurable share, paid for it with a ratio rather than with dollars, and is now at the point where th...
Read Article ›At 10.7x forward Adjusted EBITDA, FTAI Aviation is mispriced to the upside — not because consensus will be met, because it won't, but because the franchise implied by today's price is materially worse than the one the second-quarter segment disclosures describe.
Read Article ›The market spent a week repricing Lam for a demand shock that the guide, the deferred revenue and the clean-room schedule all contradict, and fiscal 2027 earnings are close to banked at a level the last eight quarters suggest is a floor rather than a target.
Read Article ›At 16 times forward earnings, this price embeds no margin expansion, no buyback, and a backlog that converts on the market's timetable rather than the contract's.
Read Article ›What kills single-asset biotechs is not usually the science; it is being forced to sell equity into bad news and AbCellera has removed that mechanism for the window in question.
Read Article ›Matador's reported earnings and its cash earnings have been separated by a contract with a termination date, and the market has been pricing the former.
Read Article ›At 15.5 times forward earnings and a 6.6% cash yield on enterprise value, the market is not pricing a debate, it is pricing an answer – and the answer it has chosen is contradicted by every disclosure FactSet has made since the shares halved.
Read Article ›The bull case needs nothing new — only that a brand posting 17% growth in its own channels, with inventory down 5% and a raised earnings guide, is not the brand that gets caught in someone else's clearance event.
Read Article ›What tips the balance is that the approval was not the whole catalyst — it was the start of a data stream that gets richer, not thinner, from here.
Read Article ›The harder, less-discussed truth about BridgeBio is that the equity sitting on top of this franchise is a thin residual behind a capital structure that private-credit and private-equity sponsors engineered to harvest the ramp first.
Read Article ›The discount as struck double-counts Argentina — once in the multiple and again in the reflex to distrust cash flows that are demonstrably Brent-linked and demonstrably deleveraging the balance sheet. The tape has earned back at least one of those two discounts.
Read Article ›